Lisa Bartels is the Director of CMC (Recombinant & Gene-therapy Product Development) at CSL, where they focus on establishing phase-appropriate CMC strategies for mAbs and recombinant protein vaccine projects. Previously, Lisa held various roles at CSL, including Associate Director and Senior Manager, where they specialized in CMC Regulatory Affairs for recombinant investigational medicinal products. They have also contributed to academia as a Lecturer in Microbiology at the University of Melbourne and served as a Visiting Scientist at VTT Biotechnology in Finland. Lisa earned a PhD in Biotechnology from The University of Queensland and has additional certifications in Biopharmaceutical Sciences and Clinical Trials Management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices